Progress of Preparation and Applications of No-Carrier-Added Radioiodinated MIBG

Radioiodinated metaiodobenzylguanidine (MIBG) is an important diagnostic agent for oncology and cardiology, or as a targeted radiotherapeutic for neuroendocrine tumors. Commercial formulations of radioiodinated MIBG (carrier-added (c.a.) *IMIBG) contain large mass amount of unlabeled MIBG, which is disadvantage to diagnosis or therapy with adverse effects in patients. High specific activity no-carrier-added radioiodinated MIBG ( n.c.a. *IMIBG) has the advantage of lower risk of adverse effects and is more suitable for clinical diagnostic and therapy. Much importance was attached to the preparation and application of n.c.a. *IMIBG, and great achievements had been made in the last 20 years. Here we considered the methods of preparation of n.c.a.*IMIBG, comparison of n.c.a. *IMIBG and c.a. *IMIBG in diagnostic and therapy, and the clinical status of n.c.a. *IMIBG.